Although this press release was expected the primary significance is that it gives further credibility to apabetalone and the RVX brand via the prestige, achievements and quality of the Clinical Steering Committee and the status achieved via approval of the FDA.

Just imagine how RVX shares listed on the NASDAQ might have reacted.

This press release clearly demonstrates that RVX is a credible biotech company with huge potential. 

Just my opinion of course.

I sometimes feel like RVX is a tightly wound up elastic band being held in place by unknown forces (risk factors). At some point a trigger or the sum of many triggers may unlease the force. The most obvious trigger would be a successful BoM. But the continuous good news on the scientific front with, for example 5, new independent research papers expected in 2018, etc could trigger a casscade. Even an epigenetic breakthrough by a competitor could open the flood gates.

Tada's Jan 8 post on Zenith is where my head is at. Perhaps this applies more to the cancer area than CVD? I don't know. Hopefully this link works.

https://agoracom.com/ir/ZenithEpigenetics/forums/discussion/topics/702833-there-is-hope-for-us/messages/2182183#message

GLTA

Toinv